92 related articles for article (PubMed ID: 21348807)
21. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
Stahmeyer JT; Rossol S; Bert F; Antoni C; Demir M; Hinrichsen H; Hüppe D; Teuber G; Wiebner B; Wedemeyer H; Krauth C
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1278-85. PubMed ID: 25144493
[TBL] [Abstract][Full Text] [Related]
22. [Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany].
Stahmeyer JT; Rossol S; Bert F; Abdelfattah M; Krauth C
Z Gastroenterol; 2014 Sep; 52(9):1041-9. PubMed ID: 25075995
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of interferon treatment for hepatitis C.
van Leeuwen DJ
JAMA; 1999 Jun; 281(22):2083-4. PubMed ID: 10367810
[No Abstract] [Full Text] [Related]
24. Cost-effectiveness of interferon treatment for hepatitis C.
Henley E
JAMA; 1999 Jun; 281(22):2083; author reply 2084. PubMed ID: 10367809
[No Abstract] [Full Text] [Related]
25. Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.
LaMori J; Tandon N; Laliberté F; Germain G; Pilon D; Lefebvre P; Prabhakar A
J Med Econ; 2016; 19(4):364-73. PubMed ID: 26624985
[TBL] [Abstract][Full Text] [Related]
26. Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data.
Ki M; Choi HY; Kim KA; Jang ES; Jeong SH
Gut Liver; 2017 Nov; 11(6):835-842. PubMed ID: 28798283
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype.
Goolsby Hunter A; Rosenblatt L; Patel C; Blauer-Peterson C; Anduze-Faris B
Curr Med Res Opin; 2017 May; 33(5):829-836. PubMed ID: 28128648
[TBL] [Abstract][Full Text] [Related]
28. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain.
Sicras-Mainar A; Navarro-Artieda R; Sáez-Zafra M
Gastroenterol Hepatol; 2018 Apr; 41(4):234-244. PubMed ID: 29287992
[TBL] [Abstract][Full Text] [Related]
29. [The burden of viral hepatitis in the Russian Federation requires reducing its progression for the long term, including chronic hepatitis C)].
Iushchuk ND; Znoĭko OO; Iakushechkina NA; Zyrianov SK; Shut'ko SA; Belyĭ PA; Kozina AN; Chapurin SA; Churilin IuIu; Lugovskikh EA
Ter Arkh; 2013; 85(12):79-85. PubMed ID: 24640674
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
Lemoine M; Thursz M
Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
[TBL] [Abstract][Full Text] [Related]
31. Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C.
Chirikov VV; Shaya FT; Mullins CD; dosReis S; Onukwugha E; Howell CD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1447-62. PubMed ID: 26524244
[TBL] [Abstract][Full Text] [Related]
32. Chronic hepatitis C-associated thrombocytopenia: aetiology and management.
Fouad YM
Trop Gastroenterol; 2013; 34(2):58-67. PubMed ID: 24377151
[TBL] [Abstract][Full Text] [Related]
33. It's time to end insurance restrictions on life-saving hepatitis C treatments.
Clary R
Am J Manag Care; 2016 May; 22(6 Spec No.):SP185-7. PubMed ID: 27266946
[No Abstract] [Full Text] [Related]
34. [Not Available].
Wolf E; Rüsenberg R
MMW Fortschr Med; 2015 Jun; 157 Suppl 2():42-5. PubMed ID: 26048120
[No Abstract] [Full Text] [Related]
35. HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation.
Cenderello G; Taramasso L; Marra D; Orcamo P; Pasa A; Di Biagio A
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):189-193. PubMed ID: 30321071
[TBL] [Abstract][Full Text] [Related]
36. [Severe mixed thrombopenia during interferon treatment for chronic viral hepatitis C].
Joseph-Reinette C; Causse X; Schoenwald M; Lagasse JP; Doumerc S; Labarière D; Ardizonne JF; Legoux JL
Presse Med; 1999 Oct; 28(29):1572-4. PubMed ID: 10544706
[TBL] [Abstract][Full Text] [Related]
37. [Splenectomy before antiviral therapy for patients with chronic hepatitis C with thrombocytopenia].
Aizawa N; Nishiguchi S
Nihon Rinsho; 2011 May; 69 Suppl 4():201-5. PubMed ID: 22096919
[No Abstract] [Full Text] [Related]
38. Sticker shock and the price of new therapies for hepatitis C: is it worth it?
Reau NS; Jensen DM
Hepatology; 2014 Apr; 59(4):1246-9. PubMed ID: 24493069
[No Abstract] [Full Text] [Related]
39. Treatment strategy for hepatitis C: a dilemma for the payers and the providers.
Haque M; Zariat A
Am J Gastroenterol; 2014 Dec; 109(12):1953-4. PubMed ID: 25470586
[No Abstract] [Full Text] [Related]
40. [Costs of modern treatment of chronic hepatitis C].
Stiefelhagen P; Sarrazin C
Med Monatsschr Pharm; 2015 Sep; 38(9):347-9. PubMed ID: 26731852
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
